

Yogesh Punekar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5999359/publications.pdf>

Version: 2024-02-01

29
papers

755
citations

567281

15
h-index

526287

27
g-index

30
all docs

30
docs citations

30
times ranked

1285
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis. <i>BMC Infectious Diseases</i> , 2021, 21, 222.	2.9	26
2	Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence. <i>HIV Medicine</i> , 2021, 22, 423-433.	2.2	21
3	Comedication prescription patterns and potential for drug-drug interactions with antiretroviral therapy in people living with human immunodeficiency virus type 1 infection in Germany. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 270-278.	1.9	8
4	Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis. <i>BMC Infectious Diseases</i> , 2019, 19, 484.	2.9	38
5	Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients. <i>Aids</i> , 2019, 33, 1739-1749.	2.2	18
6	Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients. <i>Cost Effectiveness and Resource Allocation</i> , 2019, 17, 26.	1.5	5
7	COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners. <i>International Journal of COPD</i> , 2018, Volume 14, 51-63.	2.3	13
8	Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1 Infected Treatment-Naive Patients in Russia. <i>Value in Health Regional Issues</i> , 2018, 16, 74-80.	1.2	7
9	A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population. <i>Infectious Diseases and Therapy</i> , 2018, 7, 183-195.	4.0	93
10	Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis. <i>Respiratory Research</i> , 2017, 18, 86.	3.6	22
11	Bronchodilator reliever use and its association with the economic and humanistic burden of COPD: a propensity-matched study. <i>Journal of Medical Economics</i> , 2017, 20, 28-36.	2.1	6
12	Systematic review of the association between exercise tests and patient-reported outcomes in patients with chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2017, Volume 12, 2487-2506.	2.3	24
13	Prevalence and burden of dyspnoea among COPD patients in Japan. <i>International Journal of Clinical Practice</i> , 2016, 70, 676-681.	1.7	7
14	Prevalence and Burden of Dyspnoea Among Patients with Chronic Obstructive Pulmonary Disease in Five European Countries. <i>Pulmonary Therapy</i> , 2016, 2, 59-72.	2.2	23
15	Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries. <i>PLoS ONE</i> , 2016, 11, e0152618.	2.5	90
16	Relationship Between FEV1 and Patient-Reported Outcomes Changes: Results of a Meta-Analysis of Randomized Trials in Stable COPD. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2016, 3, 519-538.	0.7	7
17	Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care. <i>Respiratory Research</i> , 2015, 16, 141.	3.6	15
18	Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK. <i>Cost Effectiveness and Resource Allocation</i> , 2015, 13, 22.	1.5	8

#	ARTICLE	IF	CITATIONS
19	Comparison of laboratory- and field-based exercise tests for COPD: a systematic review. International Journal of COPD, 2015, 10, 625.	2.3	34
20	Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis. International Journal of COPD, 2015, 10, 2495.	2.3	30
21	Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis. International Journal of COPD, 2015, 10, 1863.	2.3	14
22	Systematic Review of Humanistic and Economic Burden of Symptomatic Chronic Obstructive Pulmonary Disease. Pharmacoeconomics, 2015, 33, 467-488.	3.3	51
23	Resource Use and Costs up to Two Years Post Diagnosis Among Newly Diagnosed COPD Patients in the UK Primary Care Setting: A Retrospective Cohort Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 271-280.	1.6	12
24	Systematic Review of the Association Between Laboratory- and Field-Based Exercise Tests and Lung Function in Patients with Chronic Obstructive Pulmonary Disease - See more at: http://journal.copdfoundation.org/#sthash.NtJo2ItZ.dpuf . Chronic Obstructive Pulmonary Diseases (Miami, Fla.), 2015, 2, 321-342.	0.7	4
25	Treatment Evolution after COPD Diagnosis in the UK Primary Care Setting. PLoS ONE, 2014, 9, e105296.	2.5	53
26	COPD management costs according to the frequency of COPD exacerbations in UK primary care. International Journal of COPD, 2014, 9, 65.	2.3	89
27	COPD management costs according to the frequency of COPD exacerbations in UK primary care [Corrigendum]. International Journal of COPD, 2014, , 247.	2.3	0
28	Cost Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Combination Therapy Among Symptomatic COPD Patients. Value in Health, 2014, 17, A595.	0.3	3
29	Implications of chronic obstructive pulmonary disease (COPD) on patients's health status: A western view. Respiratory Medicine, 2007, 101, 661-669.	2.9	30